IP Library Granted Patent US 11,471,570
Granted Patent B2
US 11,471,570 · App. 16/922,865 · Granted Oct 18, 2022

Hemostatic devices and methods of use

Inventors: Satish Pulapura (Bridgewater, NJ); Fatima Buevich (Highland Park, NJ); Jorie S. Soskin (Edina, MN); Franklin R. Mansfield (Jacksonville, FL); Kai R. Worrell (Hopkins, MN); Charlie Wood (Delano, MN); Jorge Alberto Trevino Blanco (Minneapolis, MN); Narvel M. Brooks, III (Minneapolis, MN)
Assignee: MEDTRONIC, INC.
A61L31/16A61K31/496A61L31/04A61L31/10A61L31/146A61L31/148A61N1/0575A61B17/0401A61B17/11A61K31/65A61L31/042A61L2300/214A61L2300/418
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,471,570
App. No.
16/922,865
Granted
Oct 18, 2022
Kind
B2
Abstract

An anchorage device is provided that is configured to surround an implantable medical device. The anchorage device includes a substrate and a hemostatic agent. The substrate includes a first piece and a second piece that is joined with the first piece. The first piece includes the hemostatic agent and the second piece includes an active pharmaceutical ingredient. Kits, systems and methods are disclosed.

Claims (37)

1. A surgical system comprising:

an anchorage device configured to secure an implantable medical device within a patient's anatomy, the anchorage device comprising a substrate comprising a first piece and a second piece that is joined with the first piece to form a pocket configured for disposal of the implantable medical device, the first piece comprising a plurality of fibers made from a hemostatic agent, the first piece having at least one of rifampin and minocycline homogenously distributed within each of the fibers.

2. The surgical system recited in claim 1 , wherein the hemostatic agent is a first hemostatic agent, the substrate comprising a coating that covers at least a portion of the substrate, the coating comprising a second hemostatic agent.

3. The surgical system recited in claim 2 , wherein the first hemostatic agent is collagen and the second hemostatic agent is tranexamic acid.

4. The surgical system recited in claim 1 , further comprising the implantable medical device, the implantable medical device being selected from the group consisting of cardiac monitors, defibrillators, pacemakers and left ventricle assist devices.

5. The surgical system recited in claim 1 , wherein the hemostatic agent is a first hemostatic agent, the first piece and the second piece each comprising a coating that covers at least a portion of the first piece and at least a portion of the second piece, the coating comprising a second hemostatic agent.

6. The surgical system recited in claim 5 , wherein the first hemostatic agent is collagen and the second hemostatic agent is tranexamic acid.

7. The surgical system recited in claim 1 , wherein the hemostatic agent is a first hemostatic agent, the first piece comprising a first coating that covers at least a portion of the first piece, the second piece comprising a second coating that covers at least a portion of the second piece, the first coating being different from the second coating, at least one the first coating and the second coating comprising a second hemostatic agent.

8. The surgical system recited in claim 7 , wherein the first hemostatic agent is collagen and the second hemostatic agent is tranexamic acid.

9. The surgical system recited in claim 1 , wherein the hemostatic agent is a first hemostatic agent, the anchorage device comprising a polymer that covers of at least one of the first piece and the second piece, the polymer having a second hemostatic agent dispersed therein.

10. The surgical system recited in claim 9 , wherein the first hemostatic agent is collagen and the second hemostatic agent is tranexamic acid.

11. The surgical system recited in claim 9 , wherein the polymer is poly(D, L-lactide-co-glycolide).

12. The surgical system recited in claim 9 , wherein the polymer is a tyrosine-derived polyarylate.

13. The surgical system recited in claim 1 , wherein the hemostatic agent is a first hemostatic agent, the first piece comprising a first polymer that covers at least a portion of the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece, the first polymer having a second hemostatic agent dispersed therein, the second polymer having a combination of rifampin and minocycline dispersed therein.

14. The surgical system recited in claim 13 , wherein:

the first hemostatic agent is collagen;

the second hemostatic agent is tranexamic acid;

the first polymer is poly(D, L-lactide-co-glycolide); and

the second polymer is a tyrosine-derived polyarylate.

15. The surgical system recited in claim 1 , wherein the hemostatic agent is a first hemostatic agent, the first piece comprising a first polymer that covers at least a portion of the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece, the first polymer having a combination of rifampin and minocycline dispersed therein, the second polymer having a second hemostatic agent dispersed therein.

16. The surgical system recited in claim 15 , wherein:

the first hemostatic agent is collagen;

the second hemostatic agent is tranexamic acid;

the first polymer is a tyrosine-derived polyarylate; and

the second polymer is poly(D, L-lactide-co-glycolide).

17. The surgical system recited in claim 1 , wherein the first piece has rifampin and minocycline encapsulated within each of the fibers.

18. The surgical system recited in claim 1 , wherein the first piece has tranexamic acid homogenously distributed within each of the fibers.

19. A surgical system comprising:

an implantable medical device selected from the group consisting of cardiac monitors, defibrillators, pacemakers and left ventricle assist devices; and

an anchorage device configured to secure the implantable medical device within a patient's anatomy, the anchorage device comprising a substrate comprising a first piece and a second piece that is joined with the first piece to form a pocket configured for disposal of the implantable medical device, the first piece comprising a plurality of fibers made from collagen, the first piece having rifampin and minocycline homogenously distributed within each of the fibers, the first piece comprising a first polymer that covers at least a portion of the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece,

wherein the first polymer is poly(D, L-lactide-co-glycolide) and has tranexamic acid dispersed therein, and

wherein the second polymer is a tyrosine-derived polyarylate and has a combination of rifampin and minocycline dispersed therein.

20. A surgical system comprising:

an implantable medical device selected from the group consisting of cardiac monitors, defibrillators, pacemakers and left ventricle assist devices; and

an anchorage device configured to secure the implantable medical device within a patient's anatomy, the anchorage device comprising a substrate comprising a first piece and a second piece that is joined with the first piece to form a pocket configured for disposal of the implantable medical device, the first piece comprising a plurality of fibers made from collagen, the first piece having rifampin and minocycline homogenously distributed within each of the fibers, the first piece comprising a first polymer that covers at least a portion of the first piece, the second piece comprising a second polymer that covers at least a portion of the second piece,

wherein the first polymer is a tyrosine-derived polyarylate and has a combination of rifampin and minocycline dispersed therein, and

wherein the second polymer is poly(D, L-lactide-co-glycolide) and has tranexamic acid dispersed therein.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2026
From: BROOKS, NARVEL M., III
To: MEDTRONIC, INC.
Reel/Frame 074572/0903 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2020
From: PULAPURA, SATISH; BUEVICH, FATIMA; SOSKIN, JORIE S.; MANSFIELD, FRANKLIN R.; WORRELL, KAI R.; WOOD, CHARLIE; BLANCO, JORGE ALBERTO TREVINO
To: TYRX PHARMA, INC.
Reel/Frame 053975/0284 →
MERGER Recorded Oct 5, 2020
From: TYRX, INC.
To: MEDTRONIC, INC.
Reel/Frame 053975/0395 →
Continuity (3)
Division 15582935 · May 1, 2017
Provisional Application 62331193 · May 3, 2016
Related Publication 20200330656A1 · Oct 22, 2020